Mallory L Myers
Overview
Explore the profile of Mallory L Myers including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
51
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Myers M, Gallagher J, Woolfork D, Khorrami N, Park W, Maldonado-Puga S, et al.
bioRxiv
. 2024 Oct;
PMID: 39372767
Development of intranasal vaccines for respiratory viruses has gained popularity. However, currently only a live-attenuated influenza vaccine is FDA-approved for intranasal administration. Here, we focused on influenza virus as it...
2.
Myers M, Conlon M, Gallagher J, Woolfork D, Khorrami N, Park W, et al.
bioRxiv
. 2024 Oct;
PMID: 39372734
Influenza virus nucleoprotein (NP) is one of the most conserved influenza proteins. Both NP antigen and anti-NP antibodies are used as reagents in influenza diagnostic kits, with applications in both...
3.
Myers M, Gallagher J, Woolfork D, Stradtmann-Carvalho R, Maldonado-Puga S, Bock K, et al.
Front Immunol
. 2023 Sep;
14:1283355.
PMID: 37771593
[This corrects the article DOI: 10.3389/fimmu.2022.1002286.].
4.
McCraw D, Myers M, Gulati N, Prabhakaran M, Brand J, Andrews S, et al.
PLoS Pathog
. 2023 Aug;
19(8):e1011514.
PMID: 37639457
Despite the availability of seasonal vaccines and antiviral medications, influenza virus continues to be a major health concern and pandemic threat due to the continually changing antigenic regions of the...
5.
Myers M, Gallagher J, Kim A, Payne W, Maldonado-Puga S, Assimakopoulos H, et al.
Nat Commun
. 2023 Mar;
14(1):1763.
PMID: 36997521
Influenza virus infects millions of people annually and can cause global pandemics. Hemagglutinin (HA) is the primary component of commercial influenza vaccines (CIV), and antibody titer to HA is a...
6.
Myers M, Gallagher J, Woolfork D, Stradtmann-Carvalho R, Maldonado-Puga S, Bock K, et al.
Front Immunol
. 2022 Oct;
13:1002286.
PMID: 36248851
As new vaccine technologies and platforms, such as nanoparticles and novel adjuvants, are developed to aid in the establishment of a universal influenza vaccine, studying traditional influenza split/subunit vaccines should...
7.
McCraw D, Gallagher J, Torian U, Myers M, Conlon M, Gulati N, et al.
Sci Rep
. 2018 Jul;
8(1):10342.
PMID: 29985483
Influenza virus continues to be a major health problem due to the continually changing immunodominant head regions of the major surface glycoprotein, hemagglutinin (HA). However, some emerging vaccine platforms designed...
8.
Gallagher J, McCraw D, Torian U, Gulati N, Myers M, Conlon M, et al.
Vaccines (Basel)
. 2018 May;
6(2).
PMID: 29799445
Influenza viruses affect millions of people worldwide on an annual basis. Although vaccines are available, influenza still causes significant human mortality and morbidity. Vaccines target the major influenza surface glycoprotein...